You are here: Home » News-CM » Companies » News
Business Standard

Zydus Cadila receives final approval for Eletriptan Hydrobromide Tablets

Capital Market 

From USFDA

Zydus Cadila has received the final approval from the USFDA to market Eletriptan Hydrobromide Tablets, 20 mg (base) and 40 mg (base). The drug which is used in treatment of migraine, will be produced at the group's formulations manufacturing facility at the Pharma SEZ in Ahmedabad.

Powered by Capital Market - Live News

(This story has not been edited by Business Standard staff and is auto-generated from a syndicated feed.)

First Published: Mon, June 19 2017. 10:29 IST
RECOMMENDED FOR YOU
RECOMMENDED FOR YOU